PROM1 and breast carcinoma: This fusion protein dCD133KDEL was shown to represent a new biological assessment tool that can be used to determine the clinical importance of eradicating CD133-positive cells since selectively inhibited CD133+ ductal breast carcinoma cells, and cause regression of tumor growth in mice [71].